WASHINGTON, Jan 16 - Drugmaker MSN Pharmaceuticals cleared another hurdle on Thursday toward launching its generic version of Novartis' blockbuster heart-failure drug Entresto after a U.S. appeals ...

WASHINGTON -Novartis won an order from a U.S. appeals court in Washington on Thursday temporarily blocking drugmaker MSN Pharmaceuticals from launching a generic version of Novartis' blockbuster heart ...

Royalty-free licenses let you pay once to use copyrighted images and video clips in personal and commercial projects on an ongoing basis without requiring additional payments each time you use that ...

A Washington DC federal judge on Wednesday refused Novartis' NOVN.S eleventh-hour bid to block drugmaker MSN Pharmaceuticals from launching a generic version of Novartis' blockbuster heart-failure ...

The thyroid medication levothyroxine should be taken on an empty stomach at around the ... Switching brands of levothyroxine or changing to a generic may affect your symptoms or side effects. This is ...

The U.S. Court of Appeals for the Federal Circuit ordered MSN not to launch its drug, opens new tab while it considers Novartis' request for a longer ban on the generic version. The decision marks ...

WASHINGTON -Novartis won an order from a U.S. appeals court in Washington on Thursday temporarily blocking drugmaker MSN Pharmaceuticals from launching a generic version of Novartis' blockbuster ...

WASHINGTON, Jan 15 - A federal appeals court temporarily paused drugmaker MSN Pharmaceuticals' launch of a generic version of Novartis' (NOVN.S), opens new tab blockbuster heart-failure drug ...

Middle class, women, poor dominate Modi's pre-Budget speech. Relief ahead? Economic Survey offers hope to 'aam aadmi' on inflation pains, subject to terms and conditions India Inc earns fat profits ...

WASHINGTON -A federal appeals court temporarily paused drugmaker MSN Pharmaceuticals' launch of a generic version of Novartis' blockbuster heart-failure drug Entresto late on Wednesday.

Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in revenue from marking up the prices of dozens of specialty generic drugs ...

The FTC’s findings—which analyzed 51 specialty generic drugs from 2017 to 2022—showed these pharmacy benefit managers’ (PBMs') affiliated pharmacies spun up $7.3 billion in excess revenue ...